相关实验视频
Updated: Jun 10, 2025
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
1.6K
结合性激酶抑制剂和免疫疗法用于不可切除的厌塑性甲状腺癌:一个回顾性单中心研究
Yuntao Song1, Yabing Zhang1, Yanhua Bai2
1Department of Head and Neck Surgery, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China.
Oral oncology
|October 12, 2024
概括
激酶抑制剂和免疫疗法的联合治疗对不可切除的厌塑性甲状腺癌 (ATC) 有希望. 这种方法是安全有效的,特别是对于具有BRAF V600E突变的患者.
科学领域:
- 在瘤学瘤学.
- 甲状腺癌研究研究
- 癌症治疗方法 癌症治疗方法
背景情况:
- 无塑性甲状腺癌 (ATC) 是一种罕见但具有不良预后的侵袭性癌症.
- 最近的进展包括多酶抑制剂,选择性氨酸激酶抑制剂和免疫疗法.
- 评估新型组合疗法对于改善患者的治疗结果至关重要.
研究的目的:
- 评估结合酶抑制剂与抗PD-1免疫疗法的疗效和安全性.
- 为了研究这种组合作为一线治疗不可切割的ATC.
- 评估其在可切除疾病的新辅助环境中的潜力.
主要方法:
- 连续患有IVB/IVC阶段ATC的连续患者的回顾性单中心研究.
- 治疗涉及酶抑制剂 (达布拉费尼布/特拉美提尼布,伦瓦提尼布,安洛提尼布) 以及免疫检查点抑制剂 (佩姆布利祖马布,辛蒂利马布,卡梅利祖马布).
- 终点包括总生存率 (OS),无进展生存率 (PFS),反应评估和R0/R1切除可行性.
主要成果:
- 平均生存期为14.0个月,12个月生存率为55.6%.
- 与非突变患者相比,BRAF V600E突变患者的mOS (未达到) 显著更长 (4.0个月).
- 总体响应率 (ORR) 为61.1% (5个完整,6个部分响应);手术切除在38.9%是可行的.
结论:
- 激酶抑制剂和免疫治疗的联合治疗对于不可切除的ATC是安全有效的.
- 这种组合在患有BRAF V600E突变的患者中表现出特别的益处.
- 这些发现支持这种疗法作为一种有价值的第一线治疗选择.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K